Approved by regulatory authority, ‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers
Mylab Discovery Solutions has launched ‘PathoDetect HPV Detection Test’, a real-time PCR based screening solution to detect high-risk types of HPV in individuals.
Approved by regulatory authority, ‘PathoDetect HPV Detection Test’ detects and discriminates the presence of high-risk HPV strains including 16 and 18 which cause most of the cervical cancers. One of the important benefits of this test is that a woman with a positive (High Risk HPV) cervical screening result may be advised for further follow-up tests at shorter intervals. A negative test for the high-risk HPV genotypes would mean a longer interval between the next screening test.
Mylab also plans to introduce an extension of this kit which can simultaneously detect up to 15 high-risk along with discrimination of HPV 16 & 18 covering more than 95 per cent cases of cervical cancers. The test allows high throughput testing with Mylab Compact platform series automations within 2 hours.
HPV DNA testing is a recommended approach for cervical cancer screening of women over 25 and for management of those with precancerous cervical lesions.